The goal of this CORE is to provide investigators in this SPORE with high quality patient data, DNA, RNA, serum, and breast tissues from breast cancer patients and normal control patients, and to make these resources available for future translational studies. The activities of the CORE will be conducted in a way that does not compromise patient confidentiality, yet will be as comprehensive as possible in the materials that are provided. The acquisition of human biospecimens and subsequent cellular and molecular analysis of those specimens within the context of patient data are key to many translational studies of cancer. The Mayo Clinic has a strong tradition of biospecimen acquisition and centralized patient data records. Paraffin embedded tissues, histological slides, and associated patient charts from surgeries performed since the first decade of the 1900's are maintained in Mayo's Tissue Registry and the Mayo Archives. Currently, the Biospecimen and Accessioning (BAP) and the Tissue and Cell Molecular Analysis (TACMA) Shared Resources of the Mayo Clinic Cancer Center provide normal and neoplastic human tissues for cancer research at Mayo, and are resources of expertise, collaborative support, and service for pathology, immunohistochemistry, laser capture microdissection, tissue microarray preparation, and nucleic acid extraction. The Biospecimens and Patient Registry Core of this SPORE will be integrated with the existing Shared Resources in order to provide a coordinated, centralized, dedicated program for procuring, processing, and assessing biospecimens and patient data from breast cancer patients and to provide these specimens for research projects within this SPORE and to other investigators with translational research projects. This CORE will interact closely with the Biostatistics Core of this SPORE to integrate data into a single database and to provide specimens that meet the statistical requirements for translational research projects supported by this SPORE.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA116201-05
Application #
7890428
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2009-09-01
Budget End
2010-08-31
Support Year
5
Fiscal Year
2009
Total Cost
$219,410
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Wiese, Elizabeth K; Hitosugi, Taro (2018) Tyrosine Kinase Signaling in Cancer Metabolism: PKM2 Paradox in the Warburg Effect. Front Cell Dev Biol 6:79
Frank, Ryan D; Winham, Stacey J; Vierkant, Robert A et al. (2018) Evaluation of 2 breast cancer risk models in a benign breast disease cohort. Cancer 124:3319-3328
Degnim, Amy C; Winham, Stacey J; Frank, Ryan D et al. (2018) Model for Predicting Breast Cancer Risk in Women With Atypical Hyperplasia. J Clin Oncol 36:1840-1846
Ohmine, Seiga; Salisbury, Jeffrey L; Ingle, James et al. (2018) Aurora-A overexpression is linked to development of aggressive teratomas derived from human iPS cells. Oncol Rep 39:1725-1730
Kourtidis, Antonis; Anastasiadis, Panos Z (2018) Close encounters of the RNAi kind: the silencing life of the adherens junctions. Curr Opin Cell Biol 54:30-36
Leon-Ferre, Roberto A; Polley, Mei-Yin; Liu, Heshan et al. (2018) Impact of histopathology, tumor-infiltrating lymphocytes, and adjuvant chemotherapy on prognosis of triple-negative breast cancer. Breast Cancer Res Treat 167:89-99
Ho, Ming-Fen; Lummertz da Rocha, Edroaldo; Zhang, Cheng et al. (2018) TCL1A, a Novel Transcription Factor and a Coregulator of Nuclear Factor ?B p65: Single Nucleotide Polymorphism and Estrogen Dependence. J Pharmacol Exp Ther 365:700-710
Horne, Hisani N; Oh, Hannah; Sherman, Mark E et al. (2018) E-cadherin breast tumor expression, risk factors and survival: Pooled analysis of 5,933 cases from 12 studies in the Breast Cancer Association Consortium. Sci Rep 8:6574
Reese, Jordan M; Bruinsma, Elizabeth S; Nelson, Adam W et al. (2018) ER?-mediated induction of cystatins results in suppression of TGF? signaling and inhibition of triple-negative breast cancer metastasis. Proc Natl Acad Sci U S A 115:E9580-E9589
Lilyquist, Jenna; Ruddy, Kathryn J; Vachon, Celine M et al. (2018) Common Genetic Variation and Breast Cancer Risk-Past, Present, and Future. Cancer Epidemiol Biomarkers Prev 27:380-394

Showing the most recent 10 out of 473 publications